Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

TY - JOUR

T1 - Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

AU - Daver, Naval

AU - Jonas, Brian A.

AU - Medeiros, Bruno C.

AU - Patil, Upen

AU - Yan, Mark

N1 - Funding Information: The study was sponsored by F.Hoffmann-La Roche Ltd. The authors thank the patients, their families, and the participating study coordinators and support staff for their contributions to the study. The authors thank WriteSource Medical Pty Ltd, Sydney, Australia, for providing medical writing and editing support. Medical writing support was funded by F. Hoffman-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). Funding Information: ND has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Abbvie, Hanmi, Trovagene, FATE Therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck Labs, and Agios. BAJ (over the past 36 months) has served as a consultant/advisor for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; received travel reimbursement from AbbVie; and received research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. BCM and UP are employees of Genentech, Inc. MY is an employee of F. Hoffmann-La Roche Ltd. Funding Information: The authors thank the patients, their families, and the participating study coordinators and support staff for their contributions to the study. The authors thank WriteSource Medical Pty Ltd, Sydney, Australia, for providing medical writing and editing support. Medical writing support was funded by F. Hoffman-La Roche Ltd in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ).

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85134160333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134160333&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2092853

DO - 10.1080/10428194.2022.2092853

M3 - Letter

C2 - 35834732

AN - SCOPUS:85134160333

SN - 1042-8194

VL - 63

SP - 2711

EP - 2714

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -